Parexel and n-Lorem Partner to Support Development of New Therapies for Nano-rare Patients

Parexel has entered a new partnership in support of n-Lorem’s effort to discover and provide experimental antisense oligonucleotide medicines to nano-rare disease patients—1 to 30 patients worldwide—for free, for life.

Photo: Stanley Crooke, founder, CEO, and chairman of n-Lorem Foundation

“n-Lorem and Parexel demonstrate a shared passion and commitment to making a difference for nano-rare patients,” said Jamie Macdonald, CEO at Parexel.

Parexel, a global clinical research organization, brings significant expertise to the partnership, having managed approximately 400 rare disease clinical studies over the past five years that contributed to 17 FDA drug approvals.

“This collaboration exemplifies Parexel’s commitment to nano-rare patients, who present insurmountable challenges to the current healthcare systems. Together with our partners and generous donors, n-Lorem is addressing these challenges one nano-rare patient at a time,” said Stanley Crooke, founder, CEO, and chairman of n-Lorem Foundation. “Currently, n-Lorem has over 50 nano-rare patients and each patient requires both an individual natural history study and a clinical study. Parexel will provide the necessary systems to assure that each patient’s natural history and clinical studies are well managed, which will be very important as we accept more nano-rare patients and collect data that informs our future decisions and aggregate experience.”

Parexel will provide clinical operations, real-world data solutions, and expertise including medical and regulatory, alongside innovative clinical research tools that will significantly enhance and streamline n-Lorem’s therapeutic development efforts.

“Parexel’s resources and guidance from their team of leading medical, regulatory and real-world data experts will translate into more robust and supportive clinical research at n-Lorem,” said Sarah Glass, chief development officer, n-Lorem Foundation. “n-Lorem is a very nimble organization limited only in our funding and resources. Partnering with Parexel will allow us to expand our clinical research infrastructure, broadening access to n-Lorem for nano-rare patients.”

Author: Rare Daily Staff